British Journal of Haematology最新文献_第4页

Sickle cell disease and commercial aviation. A retrospective analysis of in-flight and pre-flight medical events. 镰状细胞病和商业航空。对飞行中和飞行前医疗事件的回顾性分析。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-27 DOI: 10.1111/bjh.70781

Karan S Ghatora, Mark K Cairns, Paulo M Alves, Arne de Kreuk

{"title":"Sickle cell disease and commercial aviation. A retrospective analysis of in-flight and pre-flight medical events.","authors":"Karan S Ghatora, Mark K Cairns, Paulo M Alves, Arne de Kreuk","doi":"10.1111/bjh.70781","DOIUrl":"https://doi.org/10.1111/bjh.70781","url":null,"abstract":"The cabin of an aircraft while at cruising altitude is a hypobaric hypoxic environment. The hypoxic nature of this environment may predispose sickle cell disease (SCD) passengers to vaso-occlusive episodes (VOEs). Evidence on pre-flight and in-flight events related to SCD is limited. A retrospective analysis was undertaken of records from a ground-based medical support (GBMS) provider (1.1.22-1.10.24) for pre-flight and in-flight events relating to SCD. Passenger demographics, presenting features, oxygen/analgesia use and flight characteristics were extracted. 84 pre-flight and 76 in-flight SCD-related cases were identified and analysed. Pre-flight, 73% (n = 61) were cleared to fly. 33% (n = 28) reported current symptoms or recent symptoms (≤10 days) and 31% sought oxygen for the flight/portable oxygen concentrator clearance. In-flight, analgesia was provided in 49% (non-narcotic in 37% and narcotic in 12%) of all cases. One diversion occurred (due to suspected stroke). No events were seen relating to departures from airports of high elevation. SCD-related events before or during air travel were uncommon, and current measures appear to be appropriate in the prevention of diversion.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148838730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Autoimmune neutropenia in children: Test cells versus beads and a role for pro-LL-37 and absolute neutrophil count. 儿童自身免疫性中性粒细胞减少症：测试细胞对珠细胞的作用以及pro-LL-37和绝对中性粒细胞计数的作用

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-26 DOI: 10.1111/bjh.70783

Paul Ratcliffe, Alexandra Haara Löfstedt, Mikael Sundin, Petter Höglund

{"title":"Autoimmune neutropenia in children: Test cells versus beads and a role for pro-LL-37 and absolute neutrophil count.","authors":"Paul Ratcliffe, Alexandra Haara Löfstedt, Mikael Sundin, Petter Höglund","doi":"10.1111/bjh.70783","DOIUrl":"https://doi.org/10.1111/bjh.70783","url":null,"abstract":"Autoimmune neutropenia (AIN) in early childhood is caused by autoantibodies targeting neutrophil surface antigens, most commonly CD16 (FCGR3B), and must be distinguished from congenital neutropenia, malignancy-associated neutropenia and chronic idiopathic neutropenia (CIN). In this study, the diagnostic performance of the cell-based granulocyte agglutination test (GAT) and granulocyte immunofluorescence test (GIFT) was compared with the bead-based LabScreen Multi (LSM) assay in 214-suspected AIN cases. While 36% of samples were positive for anti-CD16 antibodies in GAT or GIFT, only 19% reacted against the same antigen in LSM, primarily against weak or Immunoglobulin M (IgM)-restricted antibody responses. Patients testing positive in all three assays exhibited significantly higher pro-LL-37 levels and lower absolute neutrophil counts (ANCs), indicating preserved granulopoiesis with peripheral destruction. Our findings question the use of LSM as a standalone test in AIN diagnostics. Incorporating pro-LL-37 and ANC in AIN diagnosis may improve differentiation between antibody-mediated neutropenia and other neutropenia forms in children.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148816837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial). brentuximab vedotin和苯达莫司汀一线治疗老年人霍奇金淋巴瘤的长期结果（HALO试验）。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-26 DOI: 10.1111/bjh.70763

Andrea Gallamini, Simonetta Viviani, Davide Rapezzi, Caterina Patti, Pierre Feugier, Alessandro Rambaldi, Fontanet Bijou, Anna Borra, Cécile Borel, Tanguy Pace-Loscos, Renaud Schiappa, Stephane Chauvie, Colin Debaigt, Anna Guidetti, Olivier Humbert, Jean-Marc Schiano De Colella

{"title":"Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).","authors":"Andrea Gallamini, Simonetta Viviani, Davide Rapezzi, Caterina Patti, Pierre Feugier, Alessandro Rambaldi, Fontanet Bijou, Anna Borra, Cécile Borel, Tanguy Pace-Loscos, Renaud Schiappa, Stephane Chauvie, Colin Debaigt, Anna Guidetti, Olivier Humbert, Jean-Marc Schiano De Colella","doi":"10.1111/bjh.70763","DOIUrl":"https://doi.org/10.1111/bjh.70763","url":null,"abstract":"The Hodgkin lymphoma treatment in the elderly (eHL) is a challenge due to a narrow therapeutic window between therapy effectiveness and toxicity. Both bendamustine (Be) and brentuximab vedotin (BV) are well-tolerated, effective drugs in relapsing HL, but no data exist on Be-BV frontline treatment in eHL. The prospective, open-label, phase I/II Hodgkin lymphoma combining Adcetris® and Levact® in Old patients (HALO) study was launched (Clinical Trial.Gov Id. 02467946) to test safety and efficacy of Be-BV in untreated eHL. The mean age was 70.75 (62-79), stage IIB in 12, III in 14 and IV in 31 patients. Most had B-symptoms and an International Prognostic Score (IPS) ≥3 (39). Despite a good performance status and both a high activity of daily living (ADL) (≥6 in 85%) and instrumental activities of daily living (IADL) scores (≥8 in 77%), 68% of patients had ≥5 comorbidities, with a Cumulative Illness Rating Scale-Geriatric (CIRS)-G score >3 in 75%. A complete metabolic response (CMR) was achieved in 44/57 of patients. The 6-year overall survival (OS) and progression-free survival (PFS) in per-protocol (PP) analysis were 67% (95% confidence intertvals [CI] 53-84) and 45% (95% CI 32-65) respectively. A PFS event was observed in 35: 13 progressions (10 deaths), 13 relapses (6 deaths) and 9 deaths. Be-BV, when given in a full dose schedule, is an effective regimen for unselected, poor-risk elderly Hodgkin lymphoma (HL) patients.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148816893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of chronic myeloid leukaemia complicated by SF3B1-mutant myelodysplastic syndrome. 慢性髓性白血病合并sf3b1突变骨髓增生异常综合征1例。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-26 DOI: 10.1111/bjh.70769

LiJun Zhou, ZhaoPeng Chu, HaiYan Zhu

引用次数: 0

Sirolimus is effective for paediatric Evans syndrome and secondary autoimmune cytopenias: A retrospective cohort study. 西罗莫司对儿童埃文斯综合征和继发性自身免疫性细胞减少症有效：一项回顾性队列研究

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-26 DOI: 10.1111/bjh.70795

Maggie McNeill, Camilla Cellarius, Nethmi Illamperuma, Rachelle Zipper, Clarisse Carcao, Jillian M Baker, Sheila Butchart, Michelle Fantauzzi, Caroline Malcolmson, Reena Pabari, Diandra Rollan, Kathleen Qu, Manuel Carcao

引用次数: 0

The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes. PRIME试验：一项由研究者发起的多中心II期研究，研究多（adp -核糖）聚合酶抑制剂奥拉帕尼治疗异柠檬酸脱氢酶（IDH）突变的复发/难治性急性髓性白血病和骨髓增生异常综合征。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-26 DOI: 10.1111/bjh.70756

Rory M Shallis, Jennifer VanOudenhove, Namrata Chandhok, Justin Watts, Deepa Jeyakumar, Daniel R Reed, Jan Phillip Bewersdorf, Diane Durecki, Scott Boerner, Richard F Little, Steven D Gore, Jing Li, Xun Bao, Li Chen, Sayak Ghatak, Thomas Prebet, Ranjit S Bindra, Amer M Zeidan, Stephanie Halene

引用次数: 0

Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria. idea -cel和cilta-cel治疗复发/难治性多发性骨髓瘤的实际疗效：奥地利全国回顾性分析。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-26 DOI: 10.1111/bjh.70773

Irene Strassl, Alexander Nikoloudis, Lina Zoe Ruesing, Thomas Melchardt, Michael Leisch, Eduard Schulz, Annkristin Heine, Peter Neumeister, Normann Steiner, Dominik Wolf, Wolfgang Willenbacher, Petra Pichler-Izmir, Theresa Lentner, Johannes Clausen, Veronika Buxhofer-Ausch, Sigrid Machherndl-Spandl, Olga Saini, Dagmar Wipplinger, Holger Rumpold, Nina Worel, Werner Rabitsch, Axel Schulenburg, Hermine Agis, Maria-Theresa Krauth

{"title":"Real-world outcomes of ide-cel and cilta-cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria.","authors":"Irene Strassl, Alexander Nikoloudis, Lina Zoe Ruesing, Thomas Melchardt, Michael Leisch, Eduard Schulz, Annkristin Heine, Peter Neumeister, Normann Steiner, Dominik Wolf, Wolfgang Willenbacher, Petra Pichler-Izmir, Theresa Lentner, Johannes Clausen, Veronika Buxhofer-Ausch, Sigrid Machherndl-Spandl, Olga Saini, Dagmar Wipplinger, Holger Rumpold, Nina Worel, Werner Rabitsch, Axel Schulenburg, Hermine Agis, Maria-Theresa Krauth","doi":"10.1111/bjh.70773","DOIUrl":"https://doi.org/10.1111/bjh.70773","url":null,"abstract":"B-cell maturation antigen-directed chimeric antigen receptor (CAR) T cells have revolutionized the treatment of relapsed/refractory multiple myeloma. However, no randomized head-to-head comparison of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) is available, and real-world data suggest differences in efficacy and toxicity. We performed a nationwide retrospective real-world analysis (RWA) of Austrian patients treated with ide-cel or cilta-cel between January 2024 and July 2025. Ninety patients were included, with largely balanced baseline characteristics and frequent high-risk features. Bridging therapy was administered to 94.4% of patients, resulting in high response rates prior to lymphodepletion. After a median follow-up of 17.6 months, no early separation of the progression-free survival (PFS) curves was observed between CAR-T products. Multivariable analyses showed a trend towards improved PFS with cilta-cel, whereas true extra-medullary disease (EMD) and prior bispecific antibody treatment before T-cell apheresis were associated with inferior PFS. Although previous RWA have demonstrated an early divergence in PFS between cilta-cel and ide-cel, this pattern was not observed in our cohort. The high effectiveness of bridging therapy may have contributed to these findings. Our results support further investigation of optimal bridging strategies and treatment sequencing while highlighting the persistent unmet need of patients with true EMD.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148816882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of the adenosinergic pathway in resistance to hypomethylating agents in patients with high-risk myelodysplastic syndromes. 腺苷能途径在高危骨髓增生异常综合征患者对低甲基化药物的耐药性中的作用。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-26 DOI: 10.1111/bjh.70778

George Vrachiolias, Eleftheria Lamprianidou, Athanasios Tasis, Theodoros Spyropoulos, Despoina Dimitriou, Chryssa Kymparidou, Christina Misidou, Konstantinos Liapis, Emmanouil Spanoudakis, Maria Koffa, Menelaos Papoutselis, Iliana Stamatiou, Elsa Bernard, Elli Papaemmanuil, Ioannis Mitroulis, Ioannis Kotsianidis

引用次数: 0

Unusual combination of Snapper-Schneid bodies and lenalidomide-induced Fanconi syndrome. Snapper-Schneid体和来那度胺诱导的范可尼综合征的不寻常组合。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-26 DOI: 10.1111/bjh.70802

Gabrielle Clark, Rashmi Lahiri, Ioannis Koutsavlis

引用次数: 0

In a nutshell: Haematological immune-related adverse events. 简而言之：血液学免疫相关不良事件。

IF 3.6 2区医学

British Journal of Haematology Pub Date : 2026-08-24 DOI: 10.1111/bjh.70782

Rebecca K Leaf, Jodi V Mones

引用次数: 0